Novartis-Backed Leukemia Investigate Shows 82% Remission with CAR T Cell Therapy

A very innovative, personalized cell-based treatment for a high-risk form of the most common childhood cancer resumes to stir through clinical trials. Pediatric oncologists from Children’s Hospital of Philadelphia (CHOP) reported fresh results using T cell immunotherapy against relapsed or refractory acute lymphoblastic leukemia (ALL). Continue reading Novartis-Backed Leukemia Probe Shows 82% Remission with CAR T Cell Therapy